Comanche Biopharma
Developing the first therapy targeting a root cause of preterm preeclampsia to reduce risks for mothers and babies, including premature birth.
Developing the first therapy targeting a root cause of preterm preeclampsia to reduce risks for mothers and babies, including premature birth.
Sector
Life SciencesCategory
TherapeuticsLocation
Concord, MAInitial Investment
2021Comanche Biopharma is a maternal and fetal medicine biopharmaceutical company working to lower the risks of pregnancy and premature births worldwide. We are currently developing the world’s first treatment for preeclampsia, which affects more than 10 million women every year.